Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Thompson

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|December 23, 2008
Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson, Adrian Blaser, Robert F Anderson, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of PretomanidAndrew M Thompson, Muriel Bonnet, Ho H Lee, et al.
Journal of Medicinal Chemistry|November 13, 2010
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Iveta Kmentova, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry|March 18, 2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Brian D Palmer, Hamish S Sutherland, Adrian Blaser, et al.
Organic Process Research & Development|May 26, 2017
Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral LeishmaniasisVijay S Satam, Srinivasa Rao Pedada, Pasumpon Kamaraj, et al.
Journal of Medicinal Chemistry|August 18, 2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry|December 14, 2011
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Adrian Blaser, Brian D Palmer, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry|November 26, 2009
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Brian D Palmer, Andrew M Thompson, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry|December 9, 2009
Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chainsHamish S Sutherland, Adrian Blaser, Iveta Kmentova, et al.
Journal of Medicinal Chemistry|July 8, 2005
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinasesAndrew M Thompson, Amy M Delaney, James M Hamby, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|December 23, 2008
Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson, Adrian Blaser, Robert F Anderson, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of PretomanidAndrew M Thompson, Muriel Bonnet, Ho H Lee, et al.
Journal of Medicinal Chemistry|November 13, 2010
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Iveta Kmentova, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry|March 18, 2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Brian D Palmer, Hamish S Sutherland, Adrian Blaser, et al.
Organic Process Research & Development|May 26, 2017
Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral LeishmaniasisVijay S Satam, Srinivasa Rao Pedada, Pasumpon Kamaraj, et al.
Journal of Medicinal Chemistry|August 18, 2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)Andrew M Thompson, Hamish S Sutherland, Brian D Palmer, et al.
Journal of Medicinal Chemistry|December 14, 2011
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Adrian Blaser, Brian D Palmer, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry|November 26, 2009
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)Brian D Palmer, Andrew M Thompson, Hamish S Sutherland, et al.
Journal of Medicinal Chemistry|December 9, 2009
Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chainsHamish S Sutherland, Adrian Blaser, Iveta Kmentova, et al.
Journal of Medicinal Chemistry|July 8, 2005
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinasesAndrew M Thompson, Amy M Delaney, James M Hamby, et al.
Pageof 4